The global cannabidiol market size was valued at USD 9.95 billion in 2025 and is projected to grow from USD 11.55 billion in 2026 to USD 38.07 billion by 2034, registering a CAGR of 16.08% during the forecast period from 2026 to 2034. North America dominated the cannabidiol market with a market share of 42% in 2025.
Cannabidiol (CBD) is a natural compound extracted from the hemp plant that is widely used in wellness, personal care, pharmaceutical, and nutraceutical products. It is commonly found in oils, capsules, creams, beverages, and supplements. Demand is growing due to increasing consumer interest in natural wellness products, expanding research on CBD applications, and changing regulations supporting the use of hemp-derived products.
Download a Free Sample To learn more about this report,
Pharmaceutical-Grade Formulation Becoming More Technically Sophisticated
Formulation challenges such as low water solubility and variable oral absorption are shaping pharmaceutical CBD development around more controlled delivery systems. Researchers are applying Quality by Design methods, optimized excipients, and solid-dose formats to improve consistency; a 2026 study developed CBD orally disintegrating tablets containing 10 mg per tablet with disintegration times of about 13–15 seconds. This work supports a shift toward standardized pharmaceutical formulations with tighter control over dosage, stability, and product performance.
Regulatory Frameworks Moving Toward More Defined Oversight
Differences between drug, food, and supplement rules continue to shape how CBD products are classified and developed across regulated markets. U.S. regulators have stated that existing food and dietary-supplement pathways are not appropriate for CBD and have called for a separate framework that could address labeling, contaminant controls, content limits, and other safeguards. Clearer oversight would give manufacturers more defined requirements for product development, quality control, and compliant market participation.
Higher Consumer Spending on Non-Prescription Wellness Products and Entry of Consumer Health and Personal Care Companies Drive Market
Higher spending on self-care and wellness products increases demand for CBD-based oils, creams, balms, and other non-prescription formats in markets where such products are permitted. Consumers often purchase these products for general wellness, topical care, and relaxation-oriented routines. Retail categories such as skincare and personal care provide practical applications where CBD formulations can be positioned alongside conventional wellness products. This demand-side transition broadens the consumer base and supports higher sales across specialty retail and online channels.
Participation by consumer health and personal care companies strengthens the supply of CBD products through established manufacturing, branding, and distribution networks. Larger companies can introduce CBD-infused skincare, topical care, and wellness products through pharmacies, beauty retailers, and direct-to-consumer channels. Personal care brands entering the category also improve product availability and give consumers more standardized purchasing options. This supply-side transition expands market reach and increases the number of CBD products available across mainstream consumer channels.
Complex and Fragmented Regulatory Framework and Product Quality and Standardization Issues Restrain Market Expansion
Different CBD regulations across countries and regions create uncertainty around product approval, labeling, allowable claims, and distribution. Companies must adjust products and compliance processes for each market, which raises costs and delays commercialization. This regulatory complexity restricts geographic expansion and slows wider CBD adoption.
Inconsistent CBD concentration, purity, testing methods, and labeling can weaken confidence among consumers, retailers, and regulators. Additional quality-control and certification requirements increase operating costs and make scaling more difficult for smaller producers. These issues limit mainstream acceptance and restrain overall market growth.
Expansion of CBD Applications in Veterinary and Pet Wellness Products and Growth of CBD-Based Topical Products for Sports Recovery and Active Lifestyles Offers Growth Opportunities
Pet wellness brands, veterinary product companies, CBD ingredient suppliers, and specialty retailers represent the main players for this opportunity. CBD-based oils, chews, balms, and pet-focused formulations can create revenue through premium product lines, private-label programs, veterinary-channel partnerships, and subscription-based wellness offerings. Companies such as Charlotte’s Web and Medterra are positioned to participate through their broader CBD product capabilities.
Sports wellness brands, topical product manufacturers, fitness retailers, and CBD formulators form the key customer and commercial groups for this opportunity. Recovery creams, roll-ons, balms, and massage products can create revenue through premium formulations, athlete-focused product ranges, gym partnerships, and specialty retail channels. Companies such as cbdMD and Charlotte’s Web are positioned to benefit from established topical CBD portfolios.
Consumer Trust Erosion from Unsubstantiated Product Claims and Limited Long-Term Scientific Evidence Across Consumer Applications
The CBD market faces credibility challenges because some products are promoted with therapeutic claims that lack sufficient scientific support, making retailers and consumers more cautious about unfamiliar brands. Weak confidence can increase customer-acquisition costs and make long-term brand building more difficult across mainstream channels. The FDA continues to report concerns about CBD products marketed with unproven medical claims, illustrating how credibility issues can hinder broader commercial acceptance.
CBD companies operate in an environment where evidence on long-term safety, appropriate exposure, and interactions remains incomplete for many non-prescription applications. This uncertainty makes it harder for manufacturers to build strong evidence-based positioning and for large retailers or healthcare-linked channels to confidently expand CBD portfolios. The FDA stated in 2026 that significant questions remain about CBD safety, effectiveness, dosage, and potential interactions outside its single approved prescription use.
The hemp segment dominated the cannabidiol (CBD) market with a market share of 68% in 2025 and is also expected to register the fastest CAGR of 15.8% during the forecast period 2026–2034. Its leading position is supported by broader commercial use across wellness, personal care, food, and formulation applications, together with easier integration into large-scale CBD manufacturing.
The marijuana segment remains relevant in regulated medical and adult-use markets where higher-cannabinoid formulations and specialized product formats are permitted.
Request Customizationto receive a tailored report.
The CBD oil segment dominated the cannabidiol (CBD) market with a market share of 34% in 2025, supported by its flexibility across direct consumption, formulation, and incorporation into other CBD-based products. Its simple dosing format and wide availability across consumer wellness categories continue to support its strong market position.
The CBD topicals segment is expected to grow at the fastest CAGR of 16.9% during the forecast period 2026–2034, driven by wider use in creams, balms, lotions, and other localized personal-care formats. CBD capsules serve consumers seeking standardized portions, while tinctures remain relevant for measured liquid use. CBD vape products and other formats address narrower product preferences and specialized consumption occasions.
The pharmaceutical segment dominated the cannabidiol (CBD) market with a market share of 22% in 2025, supported by controlled formulation requirements, clinical product development, and the use of CBD in regulated therapeutic applications. Greater emphasis on product consistency, dosing precision, and quality standards strengthens its position within this segment.
The topicals segment is expected to register the fastest CAGR of 17.1% during the forecast period 2026–2034, supported by the incorporation of CBD into skincare, recovery, and localized wellness products. Tincture applications remain important for liquid formulations, while food and beverages broaden CBD use through edible formats. Dietary supplements and other applications continue to serve additional wellness and specialty product categories.
The online segment dominated the cannabidiol (CBD) market with a market share of 58% in 2025 and is also expected to grow at the fastest CAGR of 16.8% during the forecast period 2026–2034. Its strong position is supported by direct-to-consumer brand models, broader product visibility, easier comparison across formulations, and convenient access to product information.
The offline segment continues to serve consumers through pharmacies, specialty stores, wellness retailers, and other physical outlets where in-person guidance and immediate product availability remain important.
Speak to an Analystto discuss market opportunities.
The North America cannabidiol market accounted for the largest regional share of 42% in 2025, supported by established regulatory frameworks, pharmaceutical research, product-quality requirements, and a developed hemp-processing ecosystem. In the U.S., FDA oversight remains central to the market, with only specific CBD-containing drug products approved for medical use while other therapeutic claims remain subject to federal restrictions, keeping compliance and clinical evidence important for market participants.
The Canada cannabidiol market operates under the Cannabis Act, with CBD production, processing, distribution, and sale subject to federal and provincial controls. Health Canada is also exploring a potential regulatory pathway for certain non-prescription CBD-containing health products, which could reshape the country’s regulated health-product segment if implemented.
Unlock Regional Insightsto access country-level data, & regional trends.
The Europe cannabidiol market is expected to register the fastest CAGR of 17.8% during the forecast period, while regulatory assessment and product authorization remain major factors shaping commercial development. In the U.K., CBD foods are treated as novel foods and require authorization, with the Food Standards Agency maintaining a register of products linked to applications undergoing regulatory review.
The Germany and France cannabidiol markets are influenced by the broader EU novel-food framework, under which CBD extracts and isolates are classified as novel foods and therefore require regulatory assessment before qualifying food applications can enter the market. Several CBD novel-food authorization procedures were also terminated by the European Commission during 2026, reinforcing the importance of product evidence and regulatory compliance for companies operating across Europe.
The Asia Pacific cannabidiol market is supported mainly by evolving regulatory structures, pharmaceutical research, and controlled development of hemp-derived ingredients rather than uniform consumer-market access. Japan has introduced specific residual Δ9-THC limits for products and revised cannabis-related regulations, making testing and compliance central to lawful CBD-related commercial activity.
The China, South Korea, and India markets remain comparatively restrictive and regulation-led, with commercial development depending heavily on permitted pharmaceutical, research, industrial-hemp, or approved ingredient pathways. China’s cosmetic-ingredient framework has also become more structured, with the NMPA updating its inventory and safety-monitoring approach for cosmetic ingredients, reinforcing regulatory scrutiny for companies evaluating cannabinoid-adjacent formulations.
The cannabidiol (cbd) market is highly fragmented, with cannabis-focused companies, nutraceutical manufacturers, pharmaceutical developers, personal care brands, and regional CBD suppliers competing across oils, capsules, beverages, cosmetics, and therapeutic formulations. Leading players include Charlotte’s Web Holdings, Inc., Jazz Pharmaceuticals plc, CV Sciences, Inc., Medical Marijuana, Inc., and Aurora Cannabis Inc., which together are estimated to account for approximately 20–25% of the global cannabidiol (cbd) market share.
Established players compete through brand recognition, product quality, regulatory compliance, and broad distribution networks. Emerging and regional players within the Cannabidiol (CBD) Market ecosystem compete through competitive pricing, specialized formulations, localized product portfolios, and direct-to-consumer channels, helping them build positions in niche wellness and personal care segments.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Analyst
Preeti Bhagat is a research professional with around 2.5 years of experience in the market research industry, specializing in market analysis, secondary research, market estimation, forecasting, and competitive intelligence. She has developed expertise across industries including Packaging and Consumer Goods, supporting businesses with data-driven insights into market dynamics, industry trends, competitive landscapes, and growth opportunities.
Her experience includes conducting comprehensive secondary research, market sizing, demand analysis, company profiling, competitive benchmarking, and trend assessment. She has hands-on experience with structured research methodologies, including top-down and bottom-up approaches, to assess market potential, growth opportunities, and future market performance.
Hair Conditioner Market Size, Share, Growth, Forecast, 2034
Cosmetics ODM Market Size, Top Share, Demand | Industry Report, 2034
CBD Skin Care Market Size, Share, Growth, Analysis, Report, 2034
Hair Removal Wax Market Size, Share, Growth, Forecast, 2034
Teeth Whitening Market Size, Share, Growth, Analysis, Report, 2034
Alcohol Wipes Market Size, Share, Growth, Analysis, Report, 2034
We are featured on:
sales@straitsresearch.com